Antidepressants

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 6, 1997, Pages 9-25

  Frazer, Alan ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIDAZOLAM; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; ARTICLE; CHEMICAL STRUCTURE; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEDATION; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER; HUMANS; MIANSERIN; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; TRIAZOLES;

EID: 0030754230     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (155)

1. Keith SJ, Matthews SM. The value of psychiatric treatment: its efficacy in severe mental disorders. Psychopharmacol Bull 1993;29:427-430
2. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55(9, suppl A):34-39
3. Sigg EB. Tricyclic thymoleptic agents and some newer antidepressants. In: Efron DH, ed. Psychopharmacology: A Review of Progress. Washington, DC: US Government Printing Office; 1968:655-669
4. Amrein R, Allen SR, Guentert TW, et al. The pharmacology of reversible monoamine oxidase inhibitors. Br J Psychiatry 1989;155(6, suppl):66-71
5. Haefely W, Burkard WP, Cesura AM, et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 1992;106: S6-S14
6. Burton SW. A review of fluvoxamine and its uses in depression. Int Clin Psychopharmacol 1991;6(3, suppl):1-21
7. De Boer TH, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-AZA-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 1988;27:399-408
8. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52(6, suppl):4-10
9. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029
10. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984;230: 94-102
11. Cusack B, Nelson A, Eichelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-565
12. Kuhn R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 1958;115:459-464
13. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 1993;150:571-577
14. Klerman GL, Cole JO. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965;17:101-141
15. Klein DF, Gittelman R, Quitkin F, et al. Diagnosis and Drug Treatment of Psychiatric Disorders. 2nd ed. Baltimore, Md: Williams and Wilkins; 1980
16. Brotman AW, Falk WE. Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1031-1040
17. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. Arch Gen Psychiatry 1990;47:935-941
18. Kocsis JH, Croughan JL, Katz MM, et al. Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 1990;147: 621-624
19. Kline NS. Clinical experience with iproniazid (MARSILID). J Clin Exp Psychopathol 1958;19(suppl 1):72-78
20. Crane GE. Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatric Research Reports of the American Psychiatric Association 1959;8:142-152
21. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219
22. Quitkin F, Rifkin A, Klein DF. Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Arch Gen Psychiatry 1979;36:749-760
23. Murphy DL, Aulakh CS, Garrick NA. Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:545-552
24. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-139
25. Quitkin FM, Harrison W, Stewart JW, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 1991;48:319-323
26. Nolen WA, Haffmans J. Treatment resistant depression: review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants. Int Clin Psychopharmacol 1989;4: 217-228
27. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
28. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118-123
29. Shih JC. Molecular basis of human MAO A and B. Neuropsychopharmacology 1991;4:1-7
30. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. Arch Gen Psychiatry 1989;46:435-450
31. Workman EA, Short DD. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry 1993;54:5-12
32. Kinney JL, Evans RL Jr. Evaluation of amoxapine. Clinical Pharmacy 1982;1:417-424
33. Gruter W, Poldinger W. Maprotiline. Mod Probl Pharmacopsychiatry 1982; 18:17-48
34. Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry 1983;44(5, Sec 2): 148-152
35. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990;51(12, suppl B):9-12
36. Kasper S, Fuger J, Moller H-J. Comparative efficacy of antidepressants. Drugs 1992;43(2, suppl): 11-23
37. Dechant KL, Clissold P. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225-253
38. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluoxetine: new selective serotonin reuptake inhibitors. Clinical Pharmacy 1992;11:930-957
39. Murdoch D, McTavish D. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992;44:604-624
40. Montgomery SA. Selective serotonin reuptake inhibitors in the acute treatment of depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995: 1043-1051
41. Guelfi JD, White C, Hackett D. Effectiveness of venlafaxine in patients hospitalized with major depression and melancholia. J Clin Psychiatry 1995;56:450-458
42. Schweizer E, Feighner J, Mandos L, et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-108
43. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106
44. Rickels K, Robinson DS, Schweizer E, et al. Nefazodone: aspects of efficacy. J Clin Psychiatry 1995;56(6, suppl):43-16
45. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs 1995;(4, suppl):39-48
46. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-171
47. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Human Psychopharmacology 1995;10:173-180
48. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995;10:3-9
49. Frazer A, Conway P. Pharmacologic mechanisms of action of antidepressants. Psychiatr Clin North Am 1984;7:575-586
50. de Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry 1990;51(12, suppl B):4-8
51. 3H]-cyclic AMP production in slices of rat cerebral cortex. Neuropharmacology 1974;13:1131-1140
52. Vetulani J, Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 1975;257:495-496
53. Banerjee SP, Kung LS, Chanda SK. Development of β adrenergic receptor subsensitivity by antidepressants. Nature 1977;268:455-456
54. 125l-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments. J Pharmacol Exp Ther 1991;257:681-690
55. Aghajanian GK. Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. In: Youdim MBH, Lovenberg W, Sharman DF, et al, eds. Essays in Neurochemistry and Neuropharmacology, vol 3. New York, NY: John Wiley & Sons; 1978:1-33
56. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7:24S-35S
57. Sulser F. Functional aspects of the norepinephrine receptor coupled adenylate cyclase system in the limbic forebrain and its modification by drugs which precipitate or alleviate depression: molecular approaches to an understanding of affective disorders. Pharmakopsychiatr Neuro Psychopharm 1978;11:43-52
58. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226
59. George MS, Lydiard RB. Speed of onset of action of the newer antidepressants - fluoxetine and bupropion. Int Clin Psychopharmacol 1991;6: 209-217
60. Burke MJ, Preskorn SH. Short-term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1053-1065
61. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
62. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
63. Khan A, Cohen S, Dager S, et al. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Disord 1989;17:33-38
64. Prien RF, Blaine JD, Levine J. Antidepressant drug therapy: the role of the new antidepressants. Hosp Community Psychiatry 1985;36:513-516
65. Rickels K, Derivan A, Entsuah R, et al. Rapid onset of antidepressant activity with venlafaxine treatment. Depression 1995;3:146-153
66. Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994;9:245-250
67. Lader M, Lang RA, Wilson GD. Patterns of improvement of depressed inpatients. In: Maudsley Monograph No. 30. New York, NY: Oxford University Press; 1987
68. Small JG, Milstein V, Kellams JJ, et al. Comparative onset on improvement in depressive symptomatology with drug treatment, electroconvulsive therapy, and placebo. J Clin Psychopharmacol 1981;1:62S-69S
69. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993;3:127-135
70. Katz MM, Koscow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987;17:297-309
71. Tollefson GD. Antidepressant treatment and side effect considerations. J Clin Psychiatry 1991;52:(5, suppl)4-13
72. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992;53(2, suppl):61-66
73. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10(4, suppl):37-45
74. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993;54(9, suppl):14-34
75. Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35:730-738
76. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacology 1996;16:19-25
77. Aston-Jones G, Chiang C, Alexinsky T. Discharge of noradrenergic locus ceruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res 1991;88:501-520
78. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med Monogr Suppl 1989;19(suppl 16):1-40
79. Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clinical Pharmacy 1982;1:406-417
80. Rudolph RL, Derivan A. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16(suppl2):54S-59S
81. Roose SP, Glassman AH, Giardina EG, et al. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987;7:247-251
82. Cole JO, Brodkin JA. Antidepressant drug side effects. J Clin Psychiatry 1990;51(1, suppl):21-26
83. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988;26:265-271
84. Harto-Traux N, Stern WC, Miller LL, et al. Effects of bupropion on body weight. J Clin Psychiatry 1983;44(5, sec 2):183-186
85. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety 1994;10:18-46
86. Skowron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992;12:18-22
87. Krijzer F, Snelder M, Bradford D. Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model. Neuropsychobiology 1984;12:249-254
88. Wagner W, Plekkenpol B, Gray TE, et al. Review of fluvoxamine safety database. Drugs 1992;43(2, suppl):48-54
89. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52(6, suppl): 23-33
90. Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry 1992;53:443-446
91. Sachs GA, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-393
92. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(6, suppl):12-21
93. Davidson JRT. Sexual dysfunction and antidepressants. Depression 1994/ 1995;2:233-240
94. Segraves RT. Overview of sexual dysfunction complicating the treatment of depression. J Clin Psychiatry Monograph 1992;10:4-10
95. Gardner EA, Johnston JA. Bupropion-an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985;5:24-29
96. Sher M, Krieger NJ, Juergens S. Trazodone and priapism. Am J Psychiatry 1983;140:1362-1363
97. Warner MD, Peabody CA, Whiteford HA, et al. Trazodone and priapism. J Clin Psychiatry 1987;48:244-245
98. Jue SG, Dawson GW, Brogden RN. Amoxapine: a review of its pharmacology and efficacy in depressed states. Drugs 1982;24:1-23
99. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268:3441-3445
100. Montgomery SA. Suicide and antidepressants. Drugs 1992;43:24-31
101. Crome P, Newman B. Fatal tricyclic antidepressant poisoning. J R Soc Med 1979;72:649-653
102. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. BMJ 1987;295:1021-1024
103. de Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992;43 (2, suppl):40-46
104. Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet 1963;ii:849-851
105. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry 1989;155(6, suppl):38-45
106. Da Prada M, Zurcher G, Wuthrich I, et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 1988;26:S31-S56
107. Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: a reexamination. Can J Psychiatry 1984;29:707-711
108. Hill S, Yau K, Whitwam J. MAOIs to RIMAs in anesthesia: a literature review. Psychopharmacology 1992;106:S43-S45
109. Meredith TJ, Vale JA. Poisoning due to psychotropic agents. Adverse Drug Reactions and Acute Poisoning Reviews 1985;4:83-126
110. Linden CH, Rumack BH, Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med 1984;13:1137-1144
111. Van Wyck Fleet J, Manberg PJ, Miller LL, et al. Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry 1983;44(5, sec 2):191-196
112. Spiller HA, Ramoska EA, Krenzelok EP, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med 1994;12: 43-45
113. Prange AJ Jr. The pharmacology and biochemistry of depression. Dis Nerv Syst 1964;25:217-221
114. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522
115. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967;113:1237-1264
116. Lapin IP, Oxenkrug GF. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1:132-136
117. Janowsky DS, El-Yousef MK, Davis JM, et al. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972;2:632-635
118. Carlsson A, Corrodi H, Fuxe K, et al. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-meta-tyramine. Eur J Pharmacol 1969;5:357-366
119. Lemberger L, Rowe H, Carmichael R, et al. Fluoxetine, a selective serotonin uptake inhibitor. Clin Pharmacol Ther 1978;23:421-429
120. Bowden CL, Koslow SH, Hanin I, et al. Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. Clin Pharmacol Ther 1985;37:316-324
121. Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
122. Golden RN, Rudorfer MV, Sherer MA, et al. Bupropion in depression, I: biochemical effects and clinical response. Arch Gen Psychiatry 1988; 45:139-143
123. Golden RN, DeVane CL, Laizure SC, et al. Bupropion in depression, II: the role of metabolites in clinical outcome. Arch Gen Psychiatry 1988;45:145-149
124. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33:811-819
125. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418
126. Delgado PL, Price LH, Miller HL. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991;27:321-330
127. Moja EA, Cipollo P, Castoldi D, et al. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci 1989;44:971-976
128. Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-396
129. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56 (6, suppl):3-11
130. Hemrick-Luecke SK, Snoddy HD, Fuller RW. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 1994;55:479-483
131. Fuller RW, Snoddy HD, Cohen ML. Interactions of trazodone with serotonin neurons and receptors. Neuropharmacology 1984;23:539-544
132. Salazar DE, Chaikin PC, Swanson BN, et al. The effects of nefazodone and fluoxetine on platelet serotonin-uptake and whole blood serotonin. Clin Pharmacol Ther 1994;55:137
133. Maj J, Palider W, Rawlow A. Trazodone: a central serotonin antagonist and agonist. J Neural Transm 1979;44:237-248
134. Clements-Jewery S, Robson PA, Chidley LJ. Biochemical investigations into the mode of action of trazodone. Neuropharmacology 1980;19: 1165-1173
135. 2-selective adrenoceptor antagonist Org 3770 (Mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology 1995;10: S107-S118
136. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 1980;210:88-90
137. Enna SJ, Kendall DA. Interaction of antidepressants and brain neurotransmitter receptors. J Clin Psychopharmacol 1981;1:12S-16S
138. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-315
139. 2A receptors after chronic treatment with remeron. Eur Neuropsychopharmacol 1995;5:306
140. VanderMaelen CP, Braselton JP. Acute administration of the antidepressant trazodone increases noradrenergic locus ceruleus neuronal firing in rats. Archives Internationales de Pharmacodynamie et de Therapie 1990;308:13-20
141. Hauser K, Olpe H-R, Jones RSG. Trimipramine, a tricyclic antidepressant exerting atypical actions on the central noradrenergic system. Eur J Pharmacol 1985;111:23-30
142. 2-adrenoceptor antagonists mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996;277:852-860
143. 2-adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther. In press
144. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980;19:355-363
145. 2 adrenergic heteroreceptors of 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn-Schmiedebergs Archives of Pharmacology 1993; 347:266-272
146. de Montigny C, Aghajanian GK. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 1978;202:1303-1306
147. Pickel VM, Joh TH, Chan J, et al. Serotonergic terminals: ultrastructure and synaptic interaction with catecholamine-containing neurons in the medial nuclei of the solitary tracts. J Comp Neurol 1984;225:291-301
148. Segal M. Serotonergic innervation of the locus ceruleus from the dorsal raphe and its actions on responses to noxious stimuli. J Physiol (Lond) 1979;286:401-415
149. Aston-Jones G, Akaoka H, Charlety P, et al. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus ceruleus neurons. J Neurosci 1991;11:760-769
150. Shiekhattar R, Aston-Jones G. Sensory responsiveness of brain noradrenergic neurons is modulated by endogenous brain serotonin. Brain Res 1993;623:72-76
151. Ennis M, Aston-Jones G. Activation of locus ceruleus from nucleus paragigantocellularis: a new excitatory amino acid pathway in brain. J Neurosci 1988;8:3644-3657
152. 1A receptors to selectively attenuate glutamate-evoked responses of locus ceruleus neurons. Society for Neuroscience 1990;16:799
153. 2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus ceruleus neurons. Neuroscience 1993;54:409-420
154. 1A receptor regulation: effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropsychopharmacology 1991; 4:131-144
155. 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 1994;10:41-51